Evidence map›Paper›PMID 26275900›Full record

Observational studyBMJ open2015

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.

David Preiss, Laine E Thomas, Daniel M Wojdyla, Steven M Haffner, Jason M R Gill, Thomas Yates, Melanie J Davies, Rury R Holman, John J McMurray, Robert M Califf and 2 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00097786 (A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00097786 phase3completednot on this map

A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2002 to 2009Enrolled9,306ConditionsDiabetes Mellitus, Type 2ArmsValsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Effect of age and weight on physical activity.Journal of public health research · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

David PreissBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Laine E ThomasDuke Clinical Research Institute (DCRI), Duke University Medical Center, Durham, North Carolina, USA.
Daniel M WojdylaDuke Clinical Research Institute (DCRI), Duke University Medical Center, Durham, North Carolina, USA.
Steven M HaffnerDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Jason M R GillBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Thomas YatesDiabetes Research Centre, University of Leicester, Leicester, UK.
Melanie J DaviesDiabetes Research Centre, University of Leicester, Leicester, UK.
Rury R HolmanDiabetes Trials Unit, University of Oxford, Oxford, UK.
John J McMurrayBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Robert M CaliffDuke Translational Medicine Institute, Duke University Medical Center, Durham, North Carolina, USA.
William E KrausDivision of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina, USA.
NAVIGATOR Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWhile bidirectional relationships exist between body weight and physical activity, direction of causality remains uncertain and previous studies have been limited by self-reported activity or weight and small sample size. We investigated the prospective relationships between weight and physical activity.

designObservational analysis of data from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study, a double-blinded randomised clinical trial of nateglinide and valsartan, respectively.

settingMultinational study of 9306 participants.

participantsParticipants with biochemically confirmed impaired glucose tolerance had annual measurements of both weight and step count using research grade pedometers, worn for 7 days consecutively. Along with randomisation to valsartan or placebo plus nateglinide or placebo, participants took part in a lifestyle modification programme. OUTCOME MEASURES: Longitudinal regression using weight as response value and physical activity as predictor value was conducted, adjusted for baseline covariates. Analysis was then repeated with physical activity as response value and weight as predictor value. Only participants with a response value preceded by at least three annual response values were included.

resultsAdequate data were available for 2811 (30%) of NAVIGATOR participants. Previous weight (χ(2)=16.8; p<0.0001), but not change in weight (χ(2)=0.1; p=0.71) was inversely associated with subsequent step count, indicating lower subsequent levels of physical activity in heavier individuals. Change in step count (χ(2)=5.9; p=0.02) but not previous step count (χ(2)=0.9; p=0.34) was inversely associated with subsequent weight. However, in the context of trajectories already established for weight (χ(2) for previous weight measurements 747.3; p<0.0001) and physical activity (χ(2) for previous step count 432.6; p<0.0001), these effects were of limited clinical importance.

conclusionsWhile a prospective bidirectional relationship was observed between weight and physical activity, the magnitude of any effect was very small in the context of natural trajectories already established for these variables. TRIAL REGISTRATION NUMBER: NCT00097786.

Indexed as

Body WeightMotor ActivityCyclohexanesDouble-Blind MethodGlucose IntoleranceHumansHypoglycemic AgentsLife StyleMulticenter Studies as TopicNateglinidePhenylalanineProspective StudiesRandomized Controlled Trials as TopicValsartanCyclohexanesHypoglycemic AgentsNateglinidePhenylalanineValsartanEPIDEMIOLOGYNutrition < TROPICAL MEDICINE

Identifiers

PMID26275900
PMCPMC4550730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.